Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINO ACIDS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.
Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Off-label: Adjunctive therapy in catabolic states (e.g., burns, trauma, sepsis)
Total parenteral nutrition (TPN) for patients unable to ingest or absorb adequate nutrients,Supplementation in metabolic disorders (e.g., urea cycle disorders, maple syrup urine disease),Treatment of negative nitrogen balance due to trauma, burns, or surgery
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.
1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.
Not applicable (mixture of nutrients with endogenous clearance). Glucose: ~1-2 h; amino acids: ~0.5-2 h; electrolytes: vary.
Variable; endogenous amino acids: 10–30 min for clearance from plasma; administered doses: distribution half-life ~5–10 min, terminal elimination half-life ~15–30 min, reflecting rapid metabolic utilization and renal reabsorption.
Metabolized via amino acid oxidation and gluconeogenesis in the liver and kidneys. Dextrose undergoes glycolysis and oxidative phosphorylation. Electrolytes are not metabolized but excreted or retained as needed.
Amino acids are metabolized primarily in the liver via transamination, deamination, and urea cycle. Specific pathways exist for each amino acid; excess nitrogen is converted to urea.
Renal: 100% (as glucose, amino acids, and electrolytes). Biliary/fecal: negligible.
Renal: >95% as amino acids and metabolites, primarily reabsorbed; <5% unchanged. Fecal/biliary: negligible (<1%).
None for components. Amino acids: minimal (<10%).
Minimal for most amino acids (<10%); albumin and globulins bind tryptophan and aromatic amino acids (~80–90% for tryptophan).
Not applicable as a mixture; individual components distribute into total body water (0.6 L/kg) or extracellular fluid (0.2 L/kg).
0.4–0.6 L/kg (total body water); reflects equilibration with intracellular and extracellular fluid compartments.
Intravenous: 100% (only route).
Oral: ~90–100% (active transport across intestinal mucosa); IV: 100%.
In renal impairment (GFR <30 m L/min): restrict fluid and electrolytes; use specialized amino acid formulations (e.g., essential amino acid solutions). Dextrose content may cause hyperglycemia; monitor glucose. Reduce volume and electrolytes as needed. For non-dialysis patients, avoid unless specific benefits outweigh risks.
For GFR <30 m L/min: reduce dose to 0.5-1 g/kg/day; monitor serum amino acids and nitrogen balance.
In hepatic impairment (Child-Pugh class B or C): monitor for encephalopathy; amino acid load may precipitate hepatic encephalopathy. Use lower protein intake (0.6-0.8 g/kg/day) or branched-chain amino acid enriched solutions. Dextrose may exacerbate hyperglycemia; adjust insulin as needed.
Child-Pugh B or C: avoid standard formulations; use branched-chain amino acid (BCAA)-enriched solutions at 0.8-1.2 g/kg/day.
Weight-based: neonates 1-3 g/kg/day amino acids, up to 15 g/kg/day dextrose, titrated. Infants and children: 1-2 g/kg/day amino acids, 10-20% dextrose at 1-2 m L/kg/hour. Adjust electrolytes per serum levels. Use age-specific formulations; monitor growth and metabolic parameters.
0.5-2 g/kg/day IV; titrate based on age, growth, and metabolic needs.
Elderly: start at lower volume (0.5-1 L/day) due to reduced renal function and fluid reserve. Monitor glucose and electrolytes closely; dextrose load may require insulin. Amino acid dosing per protein requirements (1-1.2 g/kg/day if no renal impairment). Adjust for comorbidities.
Initiate at 0.8 g/kg/day IV, adjust based on renal function and nitrogen balance; monitor for fluid overload.
Not for intravenous injection as a sole source of nutrition. Contains aluminum that may be toxic. Use with caution in renal impairment due to aluminum accumulation. Do not administer unless solution is clear and container undamaged.
Patients receiving amino acid infusions should be monitored for metabolic acidosis, hyperammonemia, and renal function impairment. Solutions with electrolytes should not be used in patients with severe electrolyte imbalances.
Risk of hyperglycemia, especially in diabetic patients,Electrolyte imbalances (hyperkalemia, hypophosphatemia, etc.),Volume overload in patients with heart failure or renal disease,Aluminum toxicity with prolonged use, especially in renal impairment,Thrombophlebitis and infection at infusion site,Refeeding syndrome in malnourished patients
Use with caution in patients with renal impairment, hepatic failure, heart failure, or metabolic acidosis. Monitor serum electrolytes, blood urea nitrogen, and ammonia levels. Avoid rapid infusion to prevent hyperosmolarity and venous thrombosis.
Anuria or severe renal impairment without appropriate monitoring,Inborn errors of amino acid metabolism (e.g., phenylketonuria),Severe electrolyte disorders before correction,Hyperglycemia uncontrolled by insulin,Hypersensitivity to any component
Hypersensitivity to any component, inborn errors of amino acid metabolism (e.g., phenylketonuria) without specific formula, severe hyperammonemia, anuria, or metabolic acidosis.
None; parenteral nutrition bypasses gastrointestinal tract. However, monitor oral intake if transitioning to enteral nutrition.
No significant food interactions; however, enteral nutrition should be managed to avoid excessive protein intake. Patients with phenylketonuria must avoid phenylalanine-containing amino acid solutions.
No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if clearly needed. Potential fetal risks include metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) associated with maternal administration of dextrose and electrolytes, which may affect fetal homeostasis. However, no specific teratogenic effects have been documented.
Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimester-specific human data; animal studies show no teratogenicity at standard doses.
It is not known whether components of this solution are excreted in human milk. No M/P ratio available. Caution should be exercised when administered to a breastfeeding woman. The high dextrose content may affect maternal glucose levels, indirectly influencing milk composition. Consider the benefits of breastfeeding and the importance of the drug to the mother.
Amino acids are normal constituents of breast milk; supplementation likely results in increased maternal levels but endogenous secretion maintains relatively constant milk levels. M/P ratio not established; generally considered compatible with breastfeeding at recommended doses.
Pharmacokinetic changes in pregnancy may require dose adjustments: increased plasma volume and glomerular filtration rate may alter electrolyte and fluid balance; increased insulin resistance may necessitate modifications in dextrose delivery. Monitor glycemic control and adjust dextrose infusion rate accordingly. Electrolyte requirements may change; adjust based on serum levels. No specific dosing guidelines are established; individualize based on maternal clinical status and laboratory parameters.
No specific dose adjustments required for enteral amino acids. For parenteral nutrition, consider increased requirements in third trimester (protein needs up to 1.5 g/kg/day). Adjust based on maternal weight gain, renal function, and metabolic monitoring.
Contains 2.75% amino acids, 15% dextrose, and electrolytes. Ensure central line access for high osmolality (approx. 1450 m Osm/L). Monitor serum electrolytes, glucose, and fluid status. Avoid in patients with severe metabolic alkalosis or anuria. Contains sulfite, may cause allergic reactions in asthmatics.
Amino acid infusions should be administered via central line if osmolarity > 900 m Osm/L to prevent thrombophlebitis. Monitor serum ammonia and BUN in patients with hepatic or renal impairment. Use with caution in patients with inborn errors of amino acid metabolism.
This solution provides nutrition and fluids directly into your vein.,Your blood sugar and electrolyte levels will be monitored regularly.,Report any signs of infection at the IV site like redness, swelling, or warmth.,Do not stop or adjust the infusion rate yourself.
This medication provides essential building blocks for protein synthesis.,Report any signs of allergic reaction such as rash, itching, or difficulty breathing.,Inform your doctor if you have liver or kidney disease.,Do not take other protein supplements unless directed by your healthcare provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER vs AMINO ACIDS, answered by our medical review team.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by Travasol 2.75% with electrolytes in dextrose 15% is a parenteral nutrition formulation. It provides amino acids for protein synthesis, dextrose for caloric energy, and electrolytes for maintaining homeostasis. Dextrose stimulates insulin release and provides glucose for cellular metabolism. Amino acids are utilized for tissue repair and nitrogen balance. Electrolytes maintain acid-base balance, neuromuscular function, and enzymatic processes.. AMINO ACIDS is a Parenteral Nutrition Solution that works by Amino acids are building blocks for protein synthesis and serve as precursors for neurotransmitters, hormones, and other nitrogenous compounds. They modulate nitrogen balance and support cellular repair and growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINO ACIDS depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is: TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is a total parenteral nutrition (TPN) solution. Adult dosing is based on caloric and protein needs: typically 1-2 L/day intravenously, providing 15% dextrose (150 g/L) and 2.75% amino acids (27.5 g/L). Infusion rate initially 1.5-2 m L/min, adjusted to meet metabolic requirements.. The standard adult dose of AMINO ACIDS is: 1-2 g/kg/day as continuous IV infusion or as a component of parenteral nutrition.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER and AMINO ACIDS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Parenteral nutrition is essential in certain conditions; use only if. AMINO ACIDS is classified as Category C. Amino acids are essential nutrients; at physiologic doses, no teratogenic risk is established. At supraphysiologic doses, theoretical risk of metabolic imbalance exists. No trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.